Explore emerging immune mechanisms under investigation in inflammatory bowel disease (IBD) in this 60-minute interactive webinar designed for Canadian healthcare clinicians.
Gain insights into current treatment limitations, intestinal fibrosis, precision medicine and emerging therapeutic pathways, including TL1A. Through expert-led education, audience polling and moderated discussion, participants will strengthen their understanding of evolving IBD research and its potential implications for future patient care.
This program has received an unrestricted educational grant or in-kind support from Merck Canada.